High in vitro and in vivo antitumor activities of luminecent platinum(II) complexes with jatrorrhizine derivatives.
Clicks: 279
ID: 85614
2019
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Steady Performance
30.0
/100
278 views
25 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Two highly active anticancer Pt(II) complexes, [Pt(Jat1)Cl]Cl (Pt1) and [Pt(Jat2)Cl]Cl (Pt2), containing jatrorrhizine derivative ligands (Jat1 and Jat2) are described. Cell intake study showed high accumulation in cell nuclear fraction. Pt1 and Pt2 exhibited high selectivity for HeLa cancer cells (IC = 15.01 ± 1.05 nM and 1.00 ± 0.17 nM) comparing with HL-7702 normal cells (IC > 150 μM), by targeting p53 and telomerase. Pt2 containing Jat2 ligand was more potent and showed high selectivity for telomerase. It also caused mitochondria and DNA damage, sub-G1 phase arrest, and a high rate of cell apoptosis at the low dose of 1.00 nM. The HeLa tumor inhibition rate (TIR) of Pt2 was 48.8%, which was even higher than cisplatin (35.2%). In addition, Pt2 displayed green luminescent property and potent telomerase inhibition. Our findings demonstrated the promising development of platinum(II) complexes containing jatrorrhizine derivatives as novel Pt-based anti-cancer agents.
| Reference Key |
qin2019higheuropean
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Qin, Qi-Pin;Zou, Bi-Qun;Wang, Zhen-Feng;Huang, Xiao-Ling;Zhang, Ye;Tan, Ming-Xiong;Wang, Shu-Long;Liang, Hong; |
| Journal | European journal of medicinal chemistry |
| Year | 2019 |
| DOI |
S0223-5234(19)30879-7
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.